My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Altimmune, Inc. - Common Stock (NQ:ALT)

5.280 +0.010 (+0.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More ↗

May 09, 2022

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:...

Via Benzinga

Altimmune Earnings Perspective: Return On Capital Employed ↗

March 16, 2022

According to Benzinga Pro data, during Q4, Altimmune (NASDAQ:ALT) posted sales of $3.28 million. Earnings were up 28.71%, but Altimmune still reported an overall loss of $23.89...

Via Benzinga

Altimmune: Q4 Earnings Insights ↗

March 15, 2022

Altimmune (NASDAQ:ALT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Altimmune's Earnings Outlook ↗

March 11, 2022

Altimmune (NASDAQ:ALT) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity ↗

January 31, 2022

The FDA has cleared Altimmune Inc's (NASDAQ:

Via Benzinga

Earnings Scheduled For March 14, 2022 ↗

March 14, 2022

Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

December 30, 2021

Gainers Kiora Pharmaceuticals (NASDAQ:KPRX

Via Benzinga

Understanding Altimmune's Unusual Options Activity ↗

August 11, 2021

Altimmune (NASDAQ:ALT) shares experienced unusual options ...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street ↗

December 29, 2021

Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current

Via Talk Markets

ALTIMMUNE INC (ALT) Q3 2021 Earnings Call Transcript ↗

November 11, 2021

ALT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

52 Biggest Movers From Yesterday ↗

September 30, 2021

Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 29, 2021

Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana...

Via Benzinga

33 Stocks Moving In Wednesday's Mid-Day Session ↗

September 29, 2021

Gainers Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18. NuCana plc (NASDAQ: NCNA) jumped 31.4% to $3.1150. The FDA granted Fast Track designation to NuCana’s...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 29, 2021

Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6...

Via Benzinga

H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off ↗

September 28, 2021

H.C. Wainwright said that Altimmune Inc (NASDAQ:

Via Benzinga

ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34 ↗

September 28, 2021

Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.

Via InvestorPlace

Dow Set to Snap Win Streak as Tech Sector Weighs ↗

September 28, 2021

The Dow Jones Industrial Average looks ready to snap its four-day win streak, as the tech sector's recent rout catches up with the index, which was last seen down 419 points.

Via Talk Markets

Topics Stocks

Why Altimmune Stock Is Under Pressure Today ↗

September 28, 2021

Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.

Via The Motley Fool

See Why Altimmune Stock Plunged After Obesity Trial Data ↗

September 28, 2021

Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 28, 2021

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market session. The company's market cap stands at $24.5...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 27, 2021

Gainers Paratek Pharmaceuticals (NASDAQ:PRTK...

Via Benzinga

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 17, 2021

Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9...

Via Benzinga

ALTIMMUNE INC (ALT) Q2 2021 Earnings Call Transcript ↗

August 11, 2021

ALT earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 11, 2021

Gainers CohBar (NASDAQ:CWBR) stock moved upwards by 68.21% to $2.17 during Wednesday's pre-market session. The company's market cap stands at $134.0 million. The...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.